Top 5 Digital Pathology Companies

Published: November 2023


Top AI-based digital pathology companies have been meticulously selected based on a proprietary company competitiveness analysis, taking into consideration portfolio strength (in terms of type of product, type of service, type of feature, additional features, area of application, type of end-user) and funding strength (in terms of number of funding instances and funding amount). These companies are playing important role in providing efficient image analysis of digital imaging. We analyzed a comprehensive list of digital pathology companies that claim to offer digital image analysis by using innovative software based on artificial intelligence and machine learning. In this article, discover 5 leading digital pathology companies and their capabilities in this industry.


Pathology is the science of diagnosing diseases, primarily through collecting and analyzing samples of tissues, cells and body fluids. In recent years, advancements in technology and emphasis on precision medicine have paved the path for the development of artificial intelligence (AI) based digital pathology techniques for quantitative and qualitative assessment of samples. Specifically, the process of AI-based digital pathology allows scanning of slides via computer monitors, by replacing the conventional microscopic approaches. Further, by converting glass slides to images, samples can be transmitted from diagnostic centers to pathologists within a fraction of time. In addition to providing real-time guidance on risk, clinical care options and outcomes, these cutting edge systems can also help clinicians by interpreting diagnostic, prognostic and therapeutic data from a large patient population. Moreover, the use of AI for pathology applications allows a computer system to automatically learn from the patient data set, and further improve and solve diagnostic issues, without being manually programmed. Furthermore, AI is able to use the information gathered from previously analyzed datasets to build statistical algorithms in order to analyze newly introduced data and provide an appropriate response.

Looking ahead, the AI-based digital pathology market is poised for significant growth. The market size is expected to expand at a 8.3% CAGR during the forecast period of 2023-2035. This growth is anticipated to be driven by the digital revolution of pathology, which is projected to accelerate in the coming years, considering multiple growth drivers, including growing number of laboratories adopting high throughput digital scanning and software technologies to assist diagnostic practice. In addition, factors, including shortage of skilled pathologists in remote areas, increasing pathology workloads due to ageing populations, higher rate of cancer screening programs, rising complexity of pathology testing and time constraints, and requirement for pathology labs to outsource expertise in the field, also contributes significantly towards the need for AI-based digital pathology solutions. Roots Analysis has conducted an exhaustive study on Digital Pathology Market featuring the current market landscape, funding and investment trends, market size and future opportunity for the digital pathology companies, over a span of 12 years.
As the digital pathology market continues to expand, with North America as a prominent hub, the rising funding support from prominent investors will play a pivotal role in catalyzing market growth and shaping the future of digital imaging for image analysis to diagnose various disorders, including chronic diseases and cancer diagnosis. It is interesting to note that digital pathology is poised to transform patient engagement, liquid biopsy, and remote patient monitoring by providing unprecedented access to high-quality diagnostic data, enabling more precise and personalized care, and empowering patients to take an active role in their own health.

Table of Contents

The top digital pathology companies offering cutting edge software based on artificial intelligence and machine learning are listed below (in alphabetical order):

  1. Akoya Biosciences
  2. Ibex Medical Analytics
  3. Paige
  4. PathAI
  5. PROSCIA

Top 5 AI-based Digital Pathology Companies

Interested in exploring all digital pathology companies, their artificial intelligence and machine learning based cutting edge software solutions?

Discover Below the Details on Top 5 Digital Pathology Companies

This article highlights the top 5 digital pathology companies, offering artificial intelligence and machine learning based image analysis, to watch out for in this industry. These companies were chosen based on Roots Analysis’ proprietary company competitiveness analysis, taking into consideration portfolio strength (in terms of type of product, type of service, type of feature, additional features, area of application, type of end-user) and funding strength (in terms of number of funding instances and funding amount). It is essential to note that the selection of top players can differ substantially according to the defined criteria(s).

Akoya Biosciences is Revolutionizing Cancer Diagnosis by its AI-Powered Digital Pathology Imaging Solutions for Spatial Phenotyping

Akoya Biosciences - Digital Pathology

Akoya Biosciences is a US-based company that claims to provide the fastest quantitative digital pathology imaging solutions capable of highlighting spatial interactions between tumor and immune cells.  In addition, the company claims to offer full single cell imaging technologies that enable researchers to profile cells with spatial context and view how they organize and interact to impact disease development and therapeutic response.  Furthermore, the company’s primary platforms, namely PhenoCycler, PhenoImager Fusion, and PhenoImager HT, provide a full continuum of spatial phenotyping solutions in order to meet the different demands of researchers engaged in discovery, translational, and clinical research.

AI-based Digital Pathology Portfolio

S. No.         Parameter Description
1 AI Software The PhenoImager™ solution (Proxima™, inForm®, phenoptrReports & phenoptr, Phenochart), PhenoCycler™
2 Type of Service Automated Image Analysis, Image Management, Cloud-based Solution and Whole Slide Imaging
3 Type of Feature Immunohistochemistry Assay, Prognostic Algorithms, Predictive Algorithms and Multi-Modal Fusion Algorithms
4 Target Disease Indication Lung Cancer and Breast Cancer
5 Type of Assays / Biomarkers PD-1 and PD-L1
6 Area of Application Research Use
7 Type of End User Research Institutes
8 Geographical Reach North America
9 Scalability Available

 

Recent Developments:  In January 2023, Akoya Biosciences announced a partnership with Agilent Technologies to develop multiplex-immunohistochemistry diagnostic solutions for tissue analysis. This collaboration will leverage digital pathology to provide an end-to-end workflow for biomarker clinical research, aiding in the discovery and validation of biomarkers for precision cancer therapeutics.1 To know more about other digital pathology companies, their technologies and recent developments, read our full report.

Cancer Diagnosis Goes Digital as Ibex Medical Analytics' AI-Powered GALEN™ Platform and Roche's navify Digital Pathology Software Join Forces

Ibex Medical Analytics - Digital Pathology

Ibex Medical Analytics is an Israel-based company that claims to utilize artificial intelligence in order to create digital workflows and clinical-grade algorithms for cancer detection. The company’s proprietary GALEN™ platform asserts to help pathologists and healthcare professionals to reduce diagnostic mistakes, implement real-time quality control, shorten diagnosis times, and increase productivity. Further, the firm claims that, GALEN™is the first-ever AI-powered cancer diagnostics platform used in standard clinical procedure in pathology laboratories and has been widely implemented to improve accuracy during the cancer detection.

AI-based Digital Pathology Portfolio

S. No.         Parameter Description
1 AI Software GALEN™
2 Type of Service Automated Image Analysis, Image Management, Open Architecture / Interoperability / Vendor Agnostic, Laboratory Information System (LIS) / Laboratory Information Management System (LIMS) and Hospital Information System (HIS)
3 Type of Feature Immunohistochemistry Assay, Prognostic Algorithms and Predictive Algorithms
4 Target Disease Indication Breast Cancer, Prostate Cancer and Gastric Cancer
5 Type of Assays / Biomarkers NA
6 Area of Application Diagnosis and Research Use
7 Type of End User Research Institutes, Hospitals / Healthcare Institutions and Laboratories / Diagnostic Institutions
8 Geographical Reach North America, MENA and Latin America
9 Scalability NA

 

Recent Developments:  In October 2023, Ibex Medical Analytics collaborated with Roche to enhance cancer diagnosis with AI-enabled digital pathology solutions. Company’s AI algorithms are now integrated into Roche's navify Digital Pathology software platform, creating a scalable ecosystem for pathology labs.2 Earlier, in September 2023, company raised USD 55 million in Series C funding to drive adoption of AI-based digital pathology solutions for cancer diagnosis. The round was led by Sienna Venture Capital and existing investors in the company, Octopus Ventures, aMoon, Planven Entrepreneur Ventures and Dell Technologies Capital.3 To know more about other digital pathology companies, their technologies and recent developments, read our full report.

Paige and Microsoft are Building World’s Largest AI-based Digital Pathology Model for Cancer Diagnosis

Paige - Digital Pathology

Paige is a US-based company, that is engaged in providing AI-powered diagnostics for cancer. The company claims to develop a cloud-platform that assists pathology workflow and enhances the overall productivity.  It is worth mentioning that, in 2021, the company received the FDA approval for its clinical-grade AI-based digital pathology tool “Paige Prostate” for cancer diagnosis. Paige Prostate is the first AI-based pathology product to achieve de novo FDA clearance as a new technology, permitting in-vitro diagnostic (IVD) usage via Paige's FDA-cleared FullFocus® digital pathology viewer.

 

S. No.         Parameter Description
1 AI Software FullFocus®
2 Type of Service Automated Image Analysis, Open Architecture / Interoperability / Vendor Agnostic, Cloud-based Solution, Whole Slide Imaging (WSI), Laboratory Information System (LIS) / Laboratory Information Management System (LIMS) and Hospital Information System (HIS)
3 Type of Feature Prognostic Algorithms
4 Target Disease Indication Breast Cancer and Prostate Cancer
5 Type of Assays / Biomarkers NA
6 Area of Application Diagnosis and Research Use
7 Type of End User Hospitals / Healthcare Institutions and Laboratories / Diagnostic Institutions
8 Geographical Reach North America
9 Scalability Available
10 Customizability Available

 

Recent Developments:  In September 2023, Paige announced partnership with Microsoft to build the world’s largest AI model for cancer diagnosis. The model is being trained based on medical imaging data based on billions of images to identify both common and rare forms of cancer, thereby providing clinical decision support to pathologists.4 To know more about other digital pathology companies, their technologies and recent developments, read our full report.

PathAI Launched AISight™, a Cloud-based Digital Pathology Image Management System for Anatomic Pathology Laboratories

PathAI - Digital Pathology

PathAI is a US-based company, focused on providing AI-powered technologies and services for pathology. The company claims to use its proprietary AI and digital pathology cutting edge technologies to expedite and improve precision medicine. For this purpose, the firm has also established collaborations with biopharma and clinical stakeholders. Further, the company’s technology supports various biopharma activities, ranging from translational research to the development of in-vitro diagnostic devices. In addition, it provides end-to-end histopathology services for trials, including sample processing, staining, scanning and digitalization, through its CLIA-certified lab services.

AI-based Digital Pathology Portfolio

S. No.         Parameter Description
1 AI Software AISight™
2 Type of Service Automated Image Analysis, Whole Slide Imaging (WSI) and Laboratory Information System (LIS) / Laboratory Information Management System (LIMS)
3 Type of Feature Immunohistochemistry (IHC) Assay and Predictive Algorithms
4 Target Disease Indication Non-small Cell Lung Cancer, Renal Cell Carcinoma, Breast Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, and Urothelial Carcinoma
5 Type of Assays / Biomarkers PD-L1
6 Area of Application Research Use
7 Type of End User Research Institutes and Laboratories / Diagnostic Institutions
8 Geographical Reach North America
9 Customizability Available

 

Recent Developments:  In August 2023, PathAI announced commercial launch of AISight™, a cloud-based digital pathology image management system (IMS) for anatomic pathology laboratories. Further, company claims that platform can be easily integrated bidirectionally with laboratory information systems to ensure streamlined workflow adoption.5 To know more about other digital pathology companies, their technologies and recent developments, read our full report.

PROSCIA’s Platform is Assisting Pathologists with Clinical Decision Support

PROSCIA - Digital Pathology

PROSCIA, a US-based software company, claims to accelerate pathology's transition to a data-driven specialty. As per the company, its proprietary digital pathology platform- Concentriq®, offering sophisticated AI applications can be used to enhance patient outcomes and unveil new insights in order to accelerate discovery.  Further, the company also states that its technology is assisting laboratories all around the world in their transition from glass to digital, expediting research and providing better patient outcomes.

AI-based Digital Pathology Portfolio

 

S. No.         Parameter Description
1 AI Software Concentriq®
2 Type of Service Automated Image Analysis, Image Management, Open Architecture / Interoperability / Vendor Agnostic, Cloud-based Solution, Whole Slide Imaging (WSI) and Laboratory Information System (LIS) / Laboratory Information Management System (LIMS)
3 Type of Feature Immunohistochemistry (IHC) Assay, Prognostic Algorithms and Predictive Algorithms
4 Target Disease Indication Colorectal Cancer
5 Type of Assays / Biomarkers NA
6 Area of Application Diagnosis and Research Use
7 Type of End User Research Institutes, Academic Institutions and Laboratories / Diagnostic Institutions
8 Geographical Reach North America and Europe
9 Scalability Available

 

Recent Developments:  In August 2023, PROSCIA partnered with DoMore Diagnostics to combine each others’ proprietary cutting edge technologies by integrating artificial intelligence powered clinical decision support into routine pathology workflows and thereby unlocking new insights that can guide progressively precise treatment decisions and ensure optimum patient outcomes.6 To know more about other digital pathology companies, their technologies and recent developments, read our full report. 
 

What About the Other Digital Pathology Companies? Gain Market Insights on All Cutting Edge Software offered by Digital Pathology Companies 
The above presentation features ten promising players from a pool of around 80 AI-based digital pathology companies that we have compiled, offering cutting edge software for image analysis to various end user. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

About Author

Ronit Sharma

Ronit Sharma is an accomplished business research and competitive intelligence professional with over six years of experience in the pharmaceutical and healthcare industry. As a team leader at Roots Analysis, he has authored numerous multidisciplinary market research reports, and led the efforts on several bespoken consulting assignments, providing valuable insights into the latest innovations in healthcare and the digital transformation of the pharmaceutical industry. Ronit's exceptional analytical skills and strategic thinking in the field contribute to the firm's intellectual capital, empowering clients to make informed decisions in the dynamic pharmaceutical landscape. With a passion for staying at the forefront of industry advancements, Ronit specializes in identifying emerging opportunities for various stakeholders, leveraging his deep understanding of market trends and technological developments. He is committed to fostering an environment of excellence, creativity, and innovation within his team, encouraging collaboration and empowering team members to bring their best ideas to the table. 

Recently, Ronit's expertise has been recognized by the online news agency, where he was interviewed and featured as an emerging industry leader. Ronit holds a B. Tech degree in Biotechnology from Lovely Professional University and his research and thought leadership can be found in his professional blog and social media profiles, where he shares the latest insights and engages in meaningful discussions with industry peers. To ensure the highest ethical standards, Ronit openly declares no conflicts of interest in his work, ensuring unbiased and trustworthy contributions. His insights undergo rigorous editorial and peer-review processes, establishing his credibility as a thought leader within the pharmaceutical and healthcare domain. Ronit's exceptional analytical and strategic thinking skills, coupled with his commitment to excellence, make him a valuable asset to any organization in the pharmaceutical and healthcare industry.

Email: ronit.sharma@rootsanalysis.com
LinkedIn: https://www.linkedin.com/in/ron001/

Sources:1 https://www.businesswire.com/news/home/20230106005053/en/Agilent-and-Akoya-Biosciences-Announce-Partnership-to-Drive-Multiplex-Tissue-Assay-Development-for-Biopharma-Applications
Sources:2 https://diagnostics.roche.com/global/en/news-listing/2023/roche-collaborates-with-ibex-and-amazon-web-services-to-accelera.html
Sources:3 https://www.prnewswire.com/news-releases/ibex-raises-55-million-in-series-c-funding-to-drive-global-adoption-of-ai-for-cancer-diagnosis-301918990.html
Sources:4 https://www.cnbc.com/2023/09/07/microsoft-paige-building-worlds-largest-ai-model-to-detect-cancer.html
Sources:5 https://www.pathai.com/resources/pathai-announces-commercial-availability-of-aisight-digital-pathology-image-management-system-to-power-the-next-generation-of-pathology-labs/
Sources:6 https://proscia.com/news/domore-diagnostics-and-proscia-partner-to-inform-personalized-treatment-decisions-for-colorectal-cancer-patients/

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry